Benzinga · Feb 10, 2026
HB
NASDAQ · HBIO
Harvard Bioscience, Inc.
Healthcare · Medical - Instruments & Supplies
$7.97
Up+$0.06 (+0.75%)
Updated Sep 17, 2026, 9:18 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 33.49M
- P/E ratio
- -0.58
- Dividend yield
- 0.00%
- 52-week range
- $0.47 – $8.40
- Volume
- 9.08K
- Avg. volume
- 6.61M
Price performance
HBIO price history
1M range · 0 trading sessions · Daily adjusted prices
HBIO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest HBIO news
The latest Smart Investors Daily articles mentioning HBIO.
Stock researchCompany · Overview
HBIO research
Overview
Company profile and research snapshot.
Company profile
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Benchmark | Speculative Buy | — |
| Mar 16, 2026 | Benchmark | Speculative Buy | — |
| Mar 13, 2026 | Benchmark | Speculative Buy | — |
| Sep 10, 2025 | Benchmark | Speculative Buy | — |
| May 13, 2025 | Benchmark | Speculative Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 10, 2026
Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M
Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended December 31,
Benzinga · Jan 30, 2026
Harvard Bioscience Trims Footprint To Run Leaner, Faster, And Cheaper
Harvard Bioscience restructures production, closing MA plant, shifting output to US and abroad. Savings expected, costs until 2027.
Benzinga · Jan 29, 2026
Harvard Bioscience Reveals Strategic Consolidation Of Manufacturing Operations; Streamlining Production Footprint And Improving Manufacturing Efficiency Through Phased Closure Of Holliston, MA Plant; Initiative Expected To Deliver ~$3M In Cost Savings In 2027
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
